Organic compounds -- part of the class 532-570 series – Organic compounds – Heavy metal containing
Reexamination Certificate
2007-06-19
2007-06-19
Nazario-Gonzalez, Porfirio (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heavy metal containing
C514S492000
Reexamination Certificate
active
11311909
ABSTRACT:
Platinum compounds, pharmaceutically acceptable salts, and prodrugs thereof. Compositions that include the platinum compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier. Methods for using the platinum compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases.
REFERENCES:
patent: 4140707 (1979-02-01), Cleare et al.
patent: 4177263 (1979-12-01), Rosenberg et al.
patent: 4704464 (1987-11-01), Brunner et al.
patent: 5117002 (1992-05-01), Khokhar et al.
patent: 5648384 (1997-07-01), Kidani et al.
patent: 5922689 (1999-07-01), Shaw
patent: 6001817 (1999-12-01), Shaw
patent: 6011166 (2000-01-01), Valsecchi et al.
patent: 6130345 (2000-10-01), Shaw
patent: 6194403 (2001-02-01), Hu et al.
patent: 6297245 (2001-10-01), Shaw
patent: 6331559 (2001-12-01), Bingham et al.
patent: 7038071 (2006-05-01), Lal
patent: 898 614 (1984-05-01), None
patent: 2 019 397 (1979-10-01), None
patent: 2 137 198 (1984-10-01), None
patent: WO 96/16068 (1996-05-01), None
patent: WO 00/63219 (2000-10-01), None
Appleton, T.G., et al., “Amino Acid Complexes of Platinum(IV). VI. Ethylenediamine-tetraacetate (EDTA) Complexes,”Inorgica Chimica Acta, 61:51-56, 1982.
Brunner, H., et al., “Porphyrin Platinum Conjugates—New Aims,”Inorganica Chimica Acta 357:1649-1669, 2004.
Charalabopoulos, K., et al., “Antitumor and Toxic Effects on Wistar Rats of Two New Platinum Complexes,”European Journal of Clinical Investigation 32:129-133, 2002.
Craciunescu, D., and A.D. Lopez, “Relation Between Structure and Antineoplastic Activity of New Cis-Pt11(L)2(X) and PtIV(L)2(OH)2(X) Complexes, Where L-Cyclohexylamine and X2−Is the Dianion of an Organic Acid,”Anales De La Real Academia De Farmacia 50(3):389-403, 1984.
Criado, J.J., “Synthesis and Characterization of Sodiumcis-dichlorochenodeoxycholylglycinato(O,N) Platinum(II)—Cytostatic Activity,”BioMetals 12:281-288, 1999.
Fan, D., et al., “Antitumor Activity Against Human Tumor Samples ofcis-Diamminedichloroplatinum(II) and Analogues at Equivalent in Vitro Myelotoxic Concentrations,”Cancer Research 48:3135-3139, Jun. 1, 1988.
Galanski, M., “The Mode of Action of Antitumor Platinum Compounds Linked to Amino Phosphonic Acids With Particular Activity Against Bone Malignancies and the Influence of Calcium Ions Onto the DNA Binding Behavior,”Contributions to Oncology 54:435-438, 1999.
Han, I., et al., “Enhanced Antitumor Activity oftrans(±)-1,2-Diaminocyclohexaneglutamatoplatinum(II) Formulated With Stealth Liposome,”Biorgan&Medicinal Chem 11:5443-5447, 2003.
Herrera, M.C., et al., “Comparison of the Effects of Bischolylglycinatechloro-Platinum(II) Versus Cisplatin on Liver Regeneration After Partial Hepatectomy,”Anticancer Research 18:3555-3564, 1998.
Jolley, J.N., et al., “Synthesis and Antitumour Activity of Platinum (II) and Platinum (IV) Complexes and Containing Ethylenediamine-Derived Ligands Having Alcohol, Carboxylic Acid and Acetate Substituents. Crystal and Molecular Structure of [PtL4C12] H2O Where L4is Ethylenediamine-N,N′-Diacetate,”Journal of Inorganic Biochemistry 83:91-100, 2001.
Kortes, R.A., “Crystal and Molecular Structure of a Potential DNA Grove-Spanning Chelate: [MV][Pt2(hdta) C12] 4H2O (MV2+= 1,1′-Dimethyl-4-4′-bipyridinium, hdta4−= 1,6-Hexanediamine-N,N,N′N′-tetraacetate),”Inorganic Chemistry 38(22):5045-5052, Oct. 2, 1999.
Lautersztain, J., et al., “Antitumor Activity of LiposomalCis-BisN-Decyl-Iminodiacetato-1, 1-Diaminocyclohexane-Platinum (II) Against L1210 Leukemia and Metastases of M5076 Murine Reticulosarcoma,”Journal of Liposome Research 1(1):1-13, 1988-89.
Lin, F.-T., et al., “Substitution of Inosine for Chloride in [Pt2(hdta)C12]2−(hdta4−= 1,6-hexanediamine-N,N,N′,N′,-tetraacetate),”Inorganica Chimica Acta 2:124-128, 1998.
Offiong, O.E., et al., “Synthesis, Spectral and Cytotoxicity Studies of Palladium(II) and Platinum(II) Amino Acid Schiff Base Complexes,”Transition Metal Chemistry 25:369-373, 2000.
Rochon, F.D., and P.-C. Kong, “Antitumour Evaluation of Some New Platinum Compounds,”Journal of Clinical Hematology and Oncology 12(2):39-43, 1982.
Sandman, K.E., et al., “A Mechanism-Based, Solution-Phase Method for Screening Combinatorial Mixtures of Potential Platinum Anticancer Drugs,”Journal of Biological Inorganic Chemistry 3:74-80, 1998.
Akerley, W., et al., “Weekly, High-Dose Paclitaxel in Advanced Lung Carcinoma,”Cancer 97(10):2480-2486, May 15, 2003.
Baumgartner, M.R., et al. “The Interaction of Transition Metals With the Coenzyme α-Lipoic Acid: Synthesis, Structure and Characterization of Copper and Zinc Complexes,”Inorganica Chimica Acta 252:319-331, Nov. 1996.
Farrell, N., “Polynuclear Charged Platinum Compounds as a New Class of Anticancer Agents,” in L.R. Kelland and N. Farrell (eds.),Platinum-Based Drugs in Cancer Therapy, Humana Press Inc., Totowa, New Jersey, Jun. 2000, pp. 321-339.
Fuertes, M.A., et al., “Novel Concepts in the Development of Platinum Antitumor Drugs,”Curr. Med. Chem.—Anti-Cancer Agents 2(4):539-551, 2002.
Hegmans A., et al., “Novel Approaches to Polynuclear Platinum Pro-Drugs. Selective Release of Cytotoxic Platinum-Spermidine Species Through Hydrolytic Cleavage of Carbamates,”Inorg. Chem. 40(24):6108-6114, Oct. 20, 2001.
Leonetti, C., et al., “α-Tocherol Protects Against Cisplatin-Induces Toxicity Without Interfering With Antitumor Efficacy,”Int. J. Cancer 104(2):243,250, 2003.
Manzotti, C., et al., “BBR 3464: A Novel Triplatinum Complex, Exhibiting a Preclinical Profile of Antitumor Efficacy Different from Cisplatin,”Clinical Cancer Res. 6:2626-2634, Jul. 2000.
Martin-Ramos, J.D., et al., “Copper(II) and Nickel(II) Chelated With Dihydrogen Trans-1,2-Diaminocyclohexane-N,N,N′N′-Tetraacetate(2−) Ion (H2CDTA2−). Synthesis, XRD Structure and Properties of [Cu(H2CDTA)] h2O and [Ni(H2CDTA)(H2O)] 4H2O”,Polyhedron 15(3)439-446, 1996.
Pace, A., et al., “Neuroprotective Effect of Vitamin E Supplementation in Patients Treated With Cisplatin Chemotherapy,”J. Clin. Oncol. 21(5):927-391 Mar. 2003.
Qu, Y., et al., “Synthesis, Characterization, and Cytotoxicity of Trifunctional Dinuclear Platinum Complexes: Comparison of Effects of Geometry and Polyfunctionally on Biological Activity,”J. Med. Chem. 43(16):3187-3192, Jul. 20, 2000.
Serimaa, R., et al., “X-Ray Scattering Study on Amorphous, Polynuclear Platinum Uridine Complexes,”J. Am. Chem. Soc 115(22):10036-10041, Nov. 3, 1993.
Nazario-Gonzalez Porfirio
Sonus Pharmaceuticals Inc.
LandOfFree
Platinum compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Platinum compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Platinum compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3876558